Vivos Therapeutics Inc (VVOS) 뉴스

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call...

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form 8-K - Current report

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA...

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]